戻る Agenda
Session 9 Track 2: Extra/Non-Hepatic Delivery
Session Chair(s)
Jeffrey Foy, PhD
Executive Director, Toxicology, Nimbus Therapeutics, United States
Sree Rayavarapu, DVM, PhD
Toxicologist, FDA, United States
This session will describe strategies for targeting extra-hepatic organs and will feature data from sponsor programs. Delivery technologies, nonclinical study design considerations, and pharmacology, ADME, and toxicology data will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize current efforts to deliver oligonucleotide-based products to cells or organs outside of the liver
- Have a greater understanding of the challenges associated with delivering oligos to muscle, lung, and brain
Speaker(s)
Eileen Blasi, MS, MSc
Senior Director of Toxicology, Avidity Biosciences, United States
Development of a Novel Muscle-targeted Antibody Oligonucleotide Conjugate for the Treatment of Myotonic Dystrophy Type 1: Toxicology and Regulatory Approaches and Considerations
Jessica Grieves, DVM, PhD
Director, Pathology and Nonclinical Development, Ionis Pharmaceuticals, United States
Nonclinical Development of Inhaled Oligonucleotides: Nothing Good Comes Easily
Vignesh Narayan Hariharan, PhD
Instructor, University of Massachutes Medical School, United States
Speaker